期刊文献+

Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?

Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?
下载PDF
导出
摘要 Prostate cancer(PCa)is a highly prevalent malignancy and constitutes a major cause of cancer-related morbidity and mortality.It emerges through the acquisition of genetic and epigenetic alterations.Epigenetic modifications include DNA methylation,histone modifications and micro RNA deregulation.These generate heritable transformations in the expression of genes but do not change the DNA sequence.Alterations in DNA methylation(hypo and hypermethylation)are the most characterized in PCa.They lead to genomic instability and inadequate gene expression.Major and minor-specific modifications in chromatin recasting are involved in PCa,with signs suggesting a dysfunction of enzymes modified by histones.Micro RNA deregulation also contributes to the initiation of PCa,including involvement in androgen receptor signalization and apoptosis.The influence of inflammation on prostate tumor carcinogenesis is currently much better known.Recent discoveries about microbial species resident in the urinary tract suggest that these are the initiators of chronic inflammation,promoting prostate inflammatory atrophy and eventually leading to PCa.Complete characterization of the relationship between the urinary microbiome and prostatic chronic inflammation will be crucial to develop plans for the prevention of PCa.The prevalent nature of epigenetic and inflammatory alterations may provide potential biomarkers for PCa diagnosis,treatment decisions,evaluation of prognosis and posttreatment surveillance. Prostate cancer(PCa) is a highly prevalent malignancy and constitutes a major cause of cancer-related morbidity and mortality. It emerges through the acquisition of genetic and epigenetic alterations. Epigenetic modifications include DNA methylation, histone modifications and micro RNA deregulation. These generate heritable transformations in the expression of genes but do not change the DNA sequence. Alterations in DNA methylation(hypo and hypermethylation) are the most characterized in PCa. They lead to genomic instability and inadequate gene expression. Major and minor-specific modifications in chromatin recasting are involved in PCa, with signs suggesting a dysfunction of enzymes modified by histones. Micro RNA deregulation also contributes to the initiation of PCa, including involvement in androgen receptor signalization and apoptosis. The influence of inflammation on prostate tumor carcinogenesis is currently much better known. Recent discoveries about microbial species resident in the urinary tract suggest that these are the initiators of chronic inflammation, promoting prostate inflammatory atrophy and eventually leading to PCa. Complete characterization of the relationship between the urinary microbiome and prostatic chronic inflammation will be crucial to develop plans for the prevention of PCa. The prevalent nature of epigenetic and inflammatory alterations may provide potential biomarkers for PCa diagnosis,treatment decisions, evaluation of prognosis and posttreatment surveillance.
出处 《World Journal of Clinical Oncology》 CAS 2020年第2期43-52,共10页 世界临床肿瘤学杂志(英文版)
关键词 Prostate cancer EPIGENETICS DNA methylation Histone modifications Micro RNAs Inflammation Initiation and progression Prognosis Prostate cancer Epigenetics DNA methylation Histone modifications Micro RNAs Inflammation Initiation and progression Prognosis
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部